Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (Nasdaq: MRNA) has initiated a rolling submission to Health Canada for its COVID-19 vaccine candidate, mRNA-1273, following positive results from preclinical and Phase 1 studies. This submission allows for ongoing assessments of safety and efficacy data as they become available. The Canadian government has confirmed orders for 20 million doses, with delivery expected in 2021 from European production facilities. The Phase 1 analysis indicated strong immune responses were generated across all age groups, supporting the vaccine's potential effectiveness.
Moderna, Inc. (Nasdaq: MRNA) has secured a commitment of up to $56 million from DARPA to develop a mobile manufacturing prototype. This initiative aims to facilitate rapid production of vaccines and therapeutics in remote locations, aligning with DARPA's NOW program. The prototype can manufacture hundreds of doses within days, enhancing military and civilian healthcare responses. CEO Stéphane Bancel emphasized the potential for this technology to address future viral outbreaks.
Moderna, Inc. (Nasdaq: MRNA) announced the return of all rights to its respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck. The transition includes the completion of the Phase 1 study by Merck, which will then be managed by Moderna. This consolidation allows Moderna to focus on RSV vaccines for adults and children. Additionally, Moderna initiated a Phase 1 study for its other RSV candidate (mRNA-1345). The company remains committed to its collaboration with Merck in cancer vaccines while expanding its RSV vaccine efforts.
Moderna (Nasdaq: MRNA) announced the second interim analysis of its Phase 1 study for mRNA-1273, a COVID-19 vaccine. The study involved 40 healthy adults, with two doses (25 µg and 100 µg) evaluated. Results showed both doses were well-tolerated, with the 100 µg dose eliciting stronger immune responses. Notably, binding and neutralizing antibody levels were comparable between older adults and younger cohorts. The U.S. government has purchased 100 million doses with an option for 400 million more, indicating strong market potential for Moderna's vaccine.
Moderna (Nasdaq: MRNA) announced that Dr. Stephen Hoge, President, will speak at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 2:00 p.m. ET. A live webcast of the event will be available in the Investors section of Moderna's website, with a replay accessible for 30 days afterward. Moderna is focused on advancing mRNA science for transformative medicines addressing various diseases and has collaborations with major organizations like AstraZeneca and Merck.